Department of Cardiorenal Cerebrovascular Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan.
Biochem Biophys Res Commun. 2011 Jul 29;411(2):375-80. doi: 10.1016/j.bbrc.2011.06.152. Epub 2011 Jun 29.
Pioglitazone, a synthetic ligand of peroxisome proliferator-activated receptor (PPAR)γ, causes preadipocyte proliferation through a mechanism which still remains elusive. Here, to address the mechanism, we investigated the effects of PPARγ and pioglitazone on the kinetics of cyclin-dependent kinase inhibitors, especially with p16(Ink4a) (p16) centered, by employing 3T3-L1 preadipocytes. Pioglitazone promoted preadipocyte proliferation by increasing S and G(2)/M cell-cycle entry, which was accompanied by decreased p16 mRNA expression. PPARγ overexpression along with the luciferase reporter assay confirmed that PPARγ was crucial for the downregulation of p16 mRNA transcription, and that the action was augmented by pioglitazone. Thus, pioglitazone exerted cell-cycle dependent promoting effect on preadipocyte proliferation, of which mechanisms include p16-downregulation through PPARγ.
吡格列酮是过氧化物酶体增殖物激活受体 (PPAR)γ 的合成配体,通过一种尚未明确的机制导致前脂肪细胞增殖。在这里,为了解决这个机制问题,我们通过使用 3T3-L1 前脂肪细胞,研究了 PPARγ 和吡格列酮对细胞周期依赖性激酶抑制剂动力学的影响,特别是以 p16(Ink4a)(p16)为中心的影响。吡格列酮通过增加 S 和 G2/M 细胞周期进入来促进前脂肪细胞增殖,这伴随着 p16 mRNA 表达的降低。PPARγ 的过表达以及荧光素酶报告基因检测证实,PPARγ 对于 p16 mRNA 转录的下调至关重要,并且这种作用通过吡格列酮得到增强。因此,吡格列酮通过 PPARγ 对 p16 进行下调,对前脂肪细胞增殖发挥了细胞周期依赖性促进作用。